07:00 , Jun 4, 2012 |  BC Week In Review  |  Financial News

AlphaRx financial update

AlphaRx implemented a 1-for-5 reverse stock split and began trading under the symbol "ALRXD." Following the split, the company has about 19 million shares outstanding. AlphaRx Inc. (OTCBB:ALRXD), Hong Kong, China   Business: Drug delivery   Date...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

AlphaRx drug delivery, autoimmune news

AlphaRx said it will shift the primary focus of the company to digital marketing in China. The company's Indaflex missed the primary endpoints in a Phase II trial to treat osteoarthritis in 2007. Indaflex is...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Company News

AlphaRx management update

AlphaRx Inc. (OTCBB:ALRX), Hong Kong, China   Business: Drug delivery   Departed: CSO Joseph Schwarz and CMO Michael Weisspapir   ...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Company News

AlphaRx, Pacific Orient Capital Inc. deal

AlphaRx terminated its April 2010 letter of intent with Pacific Orient for the acquisition of AlphaRx's AlphaRx Canada Ltd. subsidiary and ex-U.S., Canada and Europe rights to Indaflex. AlphaRx said the agreement was terminated because...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Clinical News

AlphaRx, Gaia BioPharma preclinical data

In rats anesthetized after recognition training, injectable GAI-122 before and after anesthesia significantly improved post-anesthetic object recognition compared to untreated rats (p<0.05). In an in vitro model of oxygen-glucose deprivation, GAI-122 significantly reduced CA1 hippocampal...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

AlphaRx, Cypress Bioscience deal

Cypress will return all rights for Indaflex to AlphaRx after a May decision to discontinue funding for development of the topical cream formulation of indomethacin. At the time, Cypress said it was not funding any...
07:00 , May 24, 2010 |  BC Week In Review  |  Company News

AlphaRx, Cypress Bioscience deal

Cypress informed partner AlphaRx that it discontinued funding for development of Indaflex, a topical cream formulation of indomethacin. In 2007, Indaflex missed the primary endpoints in a Phase II trial to treat osteoarthritis (OA). AlphaRx...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Company News

AlphaRx drug delivery news

AlphaRx plans to spin out its AlphaRx Canada Ltd. subsidiary into a public company headquartered in Toronto, Canada. The newco will focus on reformulating marketed drugs using AlphaRx's drug delivery technologies in the Far East...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

AlphaRx management update

AlphaRx Inc. (OTCBB:ALRX), Richmond Hill, Ontario   Business: Drug delivery   Hired: Ruby Hui as president of AlphaRx's China operations, formerly senior project manager at New World Development Co. Ltd.   ...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

AlphaRx drug delivery, cancer news

AlphaRx announced it will establish an Asian headquarters in Hong Kong and a new R&D facility in Shanghai. The company said the move is part of its push into "greater" China and plans to develop...